Potential fungicidal effect of voriconazole against Candida spp.

International Journal of Antimicrobial Agents

Volumn 25, Issue 3, 2005, Pages 264-267

  Rubio, M Carmen ^a   Ramírez De Ocáriz, Inmaculada ^a   Gil, Joaquina ^a   Benito, Rafael ^a   Rezusta, Antonio ^b  

^a HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^b Facultad de Ciencias Humanas y de la Educación   (Spain)

Author keywords

Candida spp.; Fungicidal effect; Voriconazole

Indexed keywords

ANTIFUNGAL AGENT; FUNGICIDE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIUM COLONY; BACTERIUM ISOLATE; CANDIDA; CANDIDA ALBICANS; CANDIDA KRUSEI; CANDIDA TROPICALIS; FUNGICIDAL ACTIVITY; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

EID: 14344257318     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2004.11.007     Document Type: Article

References (28)

1. D.J. Sheehan, C.A. Hitchcock, and C.M. Sibley Current and emerging azole antifungal agents Clin Microbiol Rev 12 1999 40 79
2. M. Ruhnke Voriconazole - applications and perspectives Mycoses 45 2002 42 47
3. C.J. Clancy, and M.H. Nguyen In vitro efficacy and fungicidal activity of voriconazole against Aspergillus and Fusarium species Eur J Clin Microbiol Infect Dis 17 1998 573 575
4. A. Espinel-Ingroff Germinated and nongerminated conidial suspensions for testing of susceptibilities of Aspergillus spp. to amphotericin B, itraconazole, posaconazole, ravuconazole, and voriconazole Antimicrob Agents Chemother 45 2001 605 607
5. A. Espinel-Ingroff, K. Boyle, and D.J. Sheehan In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature Mycopathologia 150 2001 101 115
6. A. Espinel-Ingroff In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi J Clin Microbiol 39 2001 954 958
7. A. Espinel-Ingroff, E. Cantón, J. Pemán, and M. Gobernado Fungicidal activity of voriconazole against Candida krusei by time-kill curves Proceedings of the 8th Congress of the European Confederation of Medical Mycology, 25-27 August, Budapest 2002
8. C. Lass-Flörl, M. Nagl, C. Speth, H. Ulmer, M.P. Dierich, and R. Wurzner Studies of in vitro activities of voriconazole and itraconazole against Aspergillus hyphae using viability staining Antimicrob Agents Chemother 45 2001 124 128
9. E.K. Manavathu, J.L. Cutright, and P.H. Chandrasekar Organism-dependent fungicidal activities of azoles Antimicrob Agents Chemother 42 1998 3018 3021
10. E.K. Manavathu, J.L. Cutright, and P.H. Chandrasekar Comparative study of susceptibilities of germinated and ungerminated conidia of Aspergillus fumigatus to various antifungal agents J Clin Microbiol 37 1999 858 861
11. M.R. McGinnis, and L. Pasarell In vitro testing of susceptibilities of filamentous ascomycetes to voriconazole, itraconazole, and amphotericin B, with consideration of phylogenetic implications J Clin Microbiol 36 1998 2353 2355
12. E.M. Johnson, A. Szekely, and D.W. Warnock In vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi J Antimicrob Chemother 42 1998 741 745
13. Ren-Kai Li, M.A. Ciblak, N. Nordoff, L. Pasarell, D.W. Warnock, and M.R. McGinnis In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum Antimicrob Agents Chemother 44 2000 1734 1736
14. N.I. Paphitou, V.L. Ostrosky-Zeichner Paetnick, J.R.E. Rodríguez Chen, and J.H. Rex In vitro antifungal susceptibilities of Trichosporon species Antimicrob Agents Chemother 46 2002 1144 1146
15. E.J. Ernst, K. Yodoi, E.E. Roling, and M.E. Klepser Rates and extents of antifungal activities of amphotericin B, flucytosine, fluconazole, and voriconazole against Candida lusitaniae determined by microdilution, Etest, and time-kill methods Antimicrob Agents Chemother 46 2002 578 581
16. J. Frasquet, M. Romero, J. Pemán, E. Cantón, N. Aparisi, and M. Gobernado Actividad fungicida de voriconazol y caspofungina sobre Candida krusei. VII Congreso Nacional de la Sociedad Española de Quimioterapia Rev Esp Quimioterap 16 2003 116 P. AF-6
17. M.E. Klepser, D. Malone, R.E. Lewis, E.J. Ernst, and M.A. Pfaller Evaluation of voriconazole pharmacodynamics using time-kill methodology Antimicrob Agents Chemother 44 2000 1917 1920
18. M.A. Pfaller, D.J. Sheehan, and J.H. Rex Determination of fungicidal activities against yeasts and moulds: lessons learned from bactericidal testing and the need for standardization Clin Microbiol Rev 17 2004 268 280
19. M.H. Nguyen, C.J. Clancy, and V.L. Yu Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia J Infect Dis 177 1998 425 430
20. L. Rodero, S. Cordoba, and P. Cahn Time-kill curves for Cryptococcus neoformans isolated from patients with AIDS Med Mycol 38 2000 201 207
21. T.J. Walsh, G.P. Melcher, and M.G. Rinaldi Trichosporon beigelii, an emerging pathogen resistant to amphotericin B J Clin Microbiol 28 1999 1616 1622
22. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard, second ed. NCCLS document M27-A2. National Committee for Clinical Laboratory Standards, Wayne, PA; 2002.
23. L. Purkins, N. Wood, P. Ghahramani, K. Greenhalgh, M.J. Allen, and D. Kleinermans Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens Antimicrob Agents Chemother 46 2002 2546 2553
24. M.A. Pfaller, S.A. Messer, and S. Gee In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents J Clin Microbiol 37 1999 870 872
25. F. Marco, M.A. Pfaller, S. Mecer, and R.N. Jones In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp. Antimicrob Agents Chemother 42 1998 161 163
26. Methods for determining bactericidal activity of antimicrobial agents. Tentative standard NCCLS document M26-T. National Committee for Clinical Laboratory Standards, Wayne, PA; 1992.
27. M.E. Klepser, E.J. Ernst, R.E. Lewis, M.E. Ernst, and M.A. Pfaller Influence of test conditions on antifungal time-kill curve results: proposal for standardized methods Antimicrob Agents Chemother 42 1998 1207 1212
28. C. Lass-Flörl, C. Speth, G. Kofler, M.P. Dierich, E. Gunsilius, and R. Wurzner Effect of increasing inoculum sizes of Aspergillus hyphae on MICs and MFCs of antifungal agents by broth microdilution method Int J Antimicrob Agents 21 2003 229 233